Biomarkers in heart failure

Frontiers in Bioscience

Volumn 14, Issue 7, 2009, Pages 2484-2493

  Novo, Giuseppina ^a   Amoroso, Gisella Rita ^a   Fazio, Giovanni ^a   Sutera, Fiorella ^a   Novo, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Brain natriuretic peptide; Cytokines; Growth factors; Heart failure; Neuro hormonal mediators; Review

Indexed keywords

BIOLOGICAL MARKER;

HEART FAILURE; HUMAN; METABOLISM; REVIEW;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS;

EID: 63849161083     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3391     Document Type: Article

References (112)

1. B. Bozkurt, D. L. Mann: Use of Biomarkers in the Management of Heart Failure: Are We There Yet? Circulation 107, 1231-1233 (2003). (Pubitemid 36314401)
2. S. A. Jortani, S. D. Prabhu, R. Valdes Jr: Strategies for Developing Biomarkers of Heart Failure. Clin Chem 50, 265-278 (2004). (Pubitemid 38156366)
3. D. S. Lee, R. S. Vasan: Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 20, 201-210 (2005). (Pubitemid 40704877)
4. G. S. Francis, S. R. Goldsmith, T. B. Levine: The neurohumoral axis in congestive heart failure. Ann Intern Med 101, 370-377 (1984). (Pubitemid 14033790)
5. V. J. Dzau: Renal and circulatory mechanisms in congestive heart failure. Kidney Int 31, 1402-1415 (1987). (Pubitemid 17090506)
6. J. N. Cohn: Sympathetic nervous system in heart failure. Circulation 106, 2417-2418 (2002). (Pubitemid 35278794)
7. M. Nemer, N. Dali-Youcef, H Wang, A Aries, P. Paradis: Mechanisms of angiotensin II-dependent progression to heart failure. Novartis Found Symp 274, 58- 68 (2006).
8. J. N. Cohn, T. B. Levine, M. T. Olivato: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311, 819- 823 (1984). (Pubitemid 14035089)
9. I. S. Anand, L. D. Fisher, Y. T. Chiang: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278-1283 (2003). (Pubitemid 36314411)
10. A. Sigurdsson, O. Amtorp, T. Gundersen: Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J 72, 422-427 (1994). (Pubitemid 24341546)
11. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325, 293-302 (1991).
12. H. Schunkert, J. R. Ingelfinger, A. T. Hirsch: Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90, 1523-1529 (1992).
13. V. K. Raman, Y. A. Lee, K. Lindpaintner: The cardiac renin-angiotensin- aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 76, 18D-23D (1995).
14. D. E. Dostal, K. M. Baker: The Cardiac Renin-Angiotensin System: Conceptual, or a Regulator of Cardiac Function? Circ Res 85, 643-650 (1999). (Pubitemid 29467853)
15. V. J. Dzau: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153, 937- 942 (1993). (Pubitemid 23124734)
16. Y. Mizuno, M. Yoshimura, H. Yasue, T. Sakamoto, H. Ogawa, K. Kugiyama: Aldosterone production is activated in failing ventricle in humans. Circulation 103, 72-75 (2001).
17. W. Zhao, R. A. Ahokas, K. T. Weber, Y. Sun: ANG IIinduced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 291, H336-43 (2006).
18. S. Jane-Lise, S. Corda, C. Chassagne, L. Rappaport: The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Fail Rev 5, 239-250 (2000).
19. J. S. Silvestre, C. Heymes, A. Oubénaïssa, V. Robert, B. Aupetit-Faisant, A. Carayon, B. Swynghedauw, C. Delcayre: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99, 2694-2701 (1999). (Pubitemid 29237459)
20. G. M. Kuster, E. Kotlyar, M. K. Rude, D. A. Siwik, R. Liao, W. S. Colucci, F. Sam: Mineralocorticoid Receptor Inhibition Ameliorates the Transition to Myocardial Failure and Decreases Oxidative Stress and Inflammation in Mice With Chronic Pressure Overload. Circulation 111, 420-427 (2005). (Pubitemid 40204425)
21. F. Sam, W. S. Colucci: Role of endothelin-1 in myocardial failure. Proc Assoc Am Physicians 111, 417-422 (1999). (Pubitemid 29446884)
22. F. Sam, W. S. Colucci: Endothelin-1 in heart failure: does it play a role? Cardiologia 43, 889-892 (1998).
23. R. V. Beneden, O. Gurné, P. L. Selvais, S. A. Ahn, A. R. Robert, J. M. Ketelslegers, H. G. Pouleur, M. F. Rousseau: Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 10, 490-495 (2004).
24. S. Sakay, T. Miyauchi, M. Kobayashi, I. Yamaguchi, K. Goto, Y. Sugishita: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384, 353-355 (1996). (Pubitemid 26408515)
25. P. Kinnunen, O. Vuolteenaho, H. Ruskoaho: Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132 1961-1970 ( 1993). (Pubitemid 23133241)
26. H. P. Brunner-La Rocca, D. M. Kaye, R. L. Woods: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37, 1221-1227 (2001).
27. A. Maisel: B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation 105, 2328-2332 (2002).
28. J. A. de Lemos, D. K. McGuire, M. H. Drazner: Btype natriuretic peptide in cardiovascular disease. Lancet 362, 316-322 (2003). (Pubitemid 36936846)
29. P. J. Hunt, A. M. Richards, M. G. Nicholls, T. G. Yandle, R. N. Doughty, E. A. Espiner: Immunoreactive amino-terminal pro-brain natriuretic peptide (NTPROBNP): a new marker of cardiac impairment. Clin Endocrinol 47, 287-296 (1997). (Pubitemid 27395959)
30. T. J. Wang, M. G. Larson, D. Levy, E. J. Benjamin, D. Corey, E. P. Leip, R. S. Vasan: Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108, 13-16 (2003). (Pubitemid 36859013)
31. A. S. Maisel, P. Krishnaswamy, R. M. Nowak, J. McCord, J. E. Hollander, P. Duc, T. Omland, A. B. Storrow, W. T. Abraham, A. H. Wu, P. Clopton, P. G. Steg, A. Westheim, C. W. Knudsen, A. Perez, R. Kazanegra, H. C. Herrmann, P. A. McCullough: Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347, 161-167 (2002). (Pubitemid 34764819)
32. C. Mueller, A. Scholer, K. Laule-Kilian, B. Martina, C. Schindler, P. Buser, M. Pfisterer, A. P. Perruchoud: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350, 647-654 (2004). (Pubitemid 38364623)
33. N. Nagaya, T. Nishikimi, Y. Okano, M. Uematsu, T. Satoh, S. Kyotani: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31, 202-208(1998). (Pubitemid 28064743)
34. H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, I. Ding: Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43, 764-270 (2004).
35. A. M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. Frampton, J. Turner, I. G. Crozier, T. G. Yandle: B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 10, 107 2786-2792 (2003). (Pubitemid 36705987)
36. S. K. James, B. Lindahl, A. Siegbahn, M. Stridsberg, P. Venge, P. Armstrong, E. S. Barnathan, R. Califf, E. J. Topol, M. L. Simoons, L. Wallentin: N-Terminal Pro- Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV Substudy. Circulation 108, 275-281 (2003). (Pubitemid 36899016)
37. M. Richards, M. G. Nicholls, T. G. Yandle, C. Frampton, E. A. Espiner, J. G. Turner, R. C. Buttimore, J. G. Lainchbury, J. M. Elliott, H. Ikram, I. G. Crozier, D. W. Smyth: Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction. Circulation 97, 1921-1929 (1998).
38. T. Jernberg, M. Stridsberg, P. Venge, B. Lindahl: Nterminal pro-brain natriuretic peptide on admission for early risk stratification of patients with chest pain andno ST-segment elevation. J Am Coll Cardiol 40, 437-445 (2002). (Pubitemid 34833157)
39. T. Omland, A. Persson, L. Ng, R. O'Brien, T. Karlsson, J. Herlitz, M. Hartford, K. Caidahl: N-Terminal Pro-B- Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes. Circulation 106, 2913-2918 (2002). (Pubitemid 35424741)
40. T. Jernberg, B. Lindahl, A. Siegbahn: N-terminal probrain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42, 1909-1916 (2003). (Pubitemid 37485564)
41. O. Bazzino, J. J. Fuselli, F. Botto: Relative value of Nterminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-STelevation acute coronary syndromes. Eur Heart J 25, 859-866 (2004). (Pubitemid 38679945)
42. M. Galvani, F. Ottani, L. Oltrona, D. Ardissino, G. F. Gensini, A. P. Maggioni, P. M. Mannucci, N. Mininni, M. D. Prando, M. Tubaro, A. Vernocchi, C. Vecchio: NTerminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes. Circulation 110, 128-134 (2004). (Pubitemid 38924580)
43. R. S. Vasan, E. J. Benjamin, M. G. Larson, E. P. Leip, T. J. Wang, P. W. Wilson, D. Levy: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288, 1252-1259 (2002). (Pubitemid 35001328)
44. T. J. Wang, M. G. Larson, D. Levy, E. J. Benjamin, E. P. Leip, T. Omland, P. A. Wolf, R. S. Vasan: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350, 655-663 (2004). (Pubitemid 38364624)
45. M. Nakamura, F. Tanaka, S. Yonezawa, K. Satou, M. Nagano, K. Hiramori: The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 16, 1025-1029 (2003). (Pubitemid 37500797)
46. A. S. Maisel, J. Koon, P. Krishnaswamy: Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141, 367-374 (2001). (Pubitemid 32200264)
47. P. Krishnaswamy, E. Lubien, P. Clopton, J. Koon: Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 111, 274 (2001).
48. E. Lubien, A. DeMaria, P. Krishnaswamy: Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105, 595-601 (2002). (Pubitemid 34123434)
49. I. S. Anand, L. D. Fisher, Y. T. Chiang, R. Latini, S. Masson, A. P. Maggioni, R. D. Glazer, G. Tognoni, J. N. Cohn: Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278-1283 (2003). (Pubitemid 36314411)
50. P. de Groote, J. Dagorn, B. Soudan: B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43, 1584-9 (2004). (Pubitemid 38561337)
51. B. Stanek, B. Frey, M. Hülsmann, R. Berger, B. Sturm, J. Strametz-Juranek, J. Bergler-Klein, P. Moser, A. Bojic, E. Hartter, R. Pacher: Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38, 436-442 (2001). (Pubitemid 32721772)
52. J. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, W. vonScheidt: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38, 1934-1941 (2001). (Pubitemid 33116567)
53. R. Berger, M. Huelsman, K. Strecker, A. Bojic, P. Moser, B. Stanek, R. Pacher: B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure. Circulation 105, 2392-2397 (2002). (Pubitemid 34556391)
54. M. Richards, R. Doughty, M. G. Nicholls, S. MacMahon, N. Sharpe, J. Murphy, E. A. Espiner, C. Frampton, T. G. Yandle: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37, 1781-1787 (2001). (Pubitemid 32499959)
55. A. M. Richards, R. Doughty, M. G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E. A. Espiner, C. Frampton, T. G. Yandle Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction. Circulation 99, 786-792 (1999). (Pubitemid 29083019)
56. R. Sodian, M. Loebe, C. Schmitt, E. V. Potapov, H. Siniawski, J. Müller, H. Hausmann, H. R. Zurbruegg, Y. Weng, R. Hetzer: Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 38, 1942-1949 (2001). (Pubitemid 33116568)
57. K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, M. Kinoshita: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36, 1587-1593 (2000).
58. M. Yoshimura, Y. Mizuno, M. Nakayama, T. Sakamoto, S. Sugiyama, H. Kawano, H. Soejima, N. Hirai, Y. Saito, K. Nakao, H. Yasue, H. Ogawa: B-type natriureticpeptide as a marker of the effects of enalapril in patients with heart failure Am J Med 112, 716-720 (2002). (Pubitemid 34655660)
59. R. W. Troughton, C. M. Frampton, T. G. Yandle, E. A. Espiner, M. G. Nicholls, A. M. Richards: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000). (Pubitemid 30172933)
60. R. Latini, S. Masson, I. Anand, D. Judd, A. P. Maggioni, Y. T. Chiang, M. Bevilacqua, M. Salio, P. Cardano, P. H. J. M. Dunselman, N. J. Holwerda, G. Tognoni, J.N., Cohn: Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 106, 2454-2458 (2002). (Pubitemid 35278801)
61. G. Palladini, C. Campana, C. Klersy, A. Balduini, G. Vadacca, V. Perfetti, S. Perlini, L. Obici, E. Ascari, G. Melzi d'Eril, R. Moratti, G. Merlini: Serum N-Terminal Pro-Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis. Circulation 107, 2440-2445 (2003). (Pubitemid 36605226)
62. T. Poutanen, T. Tikanoja, P. Riikonen, A. Silvast, M. Perkkiö: Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 21, 2349-2356 (2003). (Pubitemid 46621873)
63. M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, J. C. Burnett Jr: Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40, 976-982 (2002). (Pubitemid 34994995)
64. M. R. Mehra, P. A. Uber, M. H. Park, R. L. Scott, H. O. Ventura, B. C. Harris, E. D. Frohlich: Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43, 1590-1595 (2004). (Pubitemid 38561338)
65. W. J. Austin, V. Bhalla, I. Hernandez-Arce, S. R. Isakson, J. Beede, P. Clopton, A. S. Maisel, R. L. Fitzgerald: Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 126, 506-512 (2006). (Pubitemid 44498499)
66. C. Carmona-Bernal, E. Quintana-Gallego, M. Villa-Gil, A. Sánchez-Armengol, A. Martínez-Martínez, F. Capote: Brain natriuretic peptide in patients with congestive heart failure and central sleep apnea. Chest 127, 1667-1673 (2005). (Pubitemid 46218793)
67. B. Bozkurt, S. B. Kribbs, F. J. Clubb Jr, L. H. Michael, V. V. Didenko, P. J. Hornsby, Y. Seta, H. Oral, F. G. Spinale, D. L. Mann: Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor-alfa Promote Progressive Left Ventricular Dysfunction and Remodeling in Rats. Circulation 97, 1382-1391 (1998). (Pubitemid 28182677)
68. K. Nakamura, K. Fushimi, H. Kouchi, K. Mihara, M. Miyazaki, T. Ohe, M. Namba: Inhibitory Effects of Antioxidants on Neonatal Rat Cardiac Myocyte Hypertrophy Induced by Tumor Necrosis Factor-alpha and Angiotensin II. Circulation 98, 794-799 (1998). (Pubitemid 28391845)
69. S. D. Anker, A. J. Coats: How to recover from renaissance? the significance of the results of recover, renaissance, renewal and attach. Int J Cardiol 86, 123-130 (2002). (Pubitemid 35284800)
70. Y. Sato, T. Kita, Y. Takatsu, T. Kimura: Biochemical markers of myocyte injury in heart failure. Heart 90, 1110- 1113 (2004). (Pubitemid 39279891)
71. A. Yilmaz, K. Yalta, O. O. Turgut, M. B. Yilmaz, A. Ozyol, O. Kendirlioglu, F. Karadas, I. Tandogan: Clinical importance of elevated CK-MB and troponin I levels in congestive heart failure. Adv Ther 23, 1060-1067 (2006). (Pubitemid 46341063)
72. Y. Nishio, Y. Sato, R. Taniguchi, S. Shizuta, T. Doi, T. Morimoto, T. Kimura, T. Kita: Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ J 71, 631-635 (2007). (Pubitemid 46683349)
73. G. Torre-Amione, S. Kapadia, C. Benedict, H. Oral, J. B. Young, D. L. Mann: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27, 1201-1206 (1996). (Pubitemid 26117714)
74. M. Testa, M. Yeh, P. Lee, R. Fanelli, F. Loperfido, J. W. Berman, T. H. LeJemtel: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension J Am Coll Cardiol 28, 964-971 (1996). (Pubitemid 26348163)
75. E. R. Mohler 3rd, L. C. Sorensen, J. K. Ghali, D. D. Schocken, P. W. Willis, J. A. Bowers, A. B. Cropp, M. L. Pressler: Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 30, 35-41 (1997). (Pubitemid 27357124)
76. A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, D. L. Mann: Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST). Circulation 103, 2055-2059 (2001). (Pubitemid 32373007)
77. R. Ferrari, T. Bachetti, R. Confortini, C. Opasich, O. Febo, A. Corti, G. Cassani, O. Visioli: Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure. Circulation 92, 1479-1486 (1995).
78. M. Rauchhaus, W. Doehner, D. P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H. D. Volk, A. J. S. Coats, S. D. Anker: Plasma Cytokine Parameters and Mortality in Patients with Chronic Heart Failure. Circulation 102, 3060-3067 (2000).
79. R. S. Vasan, L. M. Sullivan, R. Roubenoff, C. A. Dinarello, T. Harris, E. J. Benjamin, D. B. Sawyer, D. Levy, P. W. F. Wilson, R. B. D'Agostino: Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study. Circulation 107, 1486-1491 (2003). (Pubitemid 36378485)
80. D. R. Murray, G. L. Freeman: Proinflammatory Cytokines: Predictors of a Failing Heart? Circulation 107, 1460-1462 (2003). (Pubitemid 36378479)
81. S. R. Kapadia, K. Yakoob, S. Nader, J. D. Thomas, D. L. Mann, B. P. Griffin: Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 36, 208-212 (2000). (Pubitemid 30466135)
82. J. Lommi, K. Pulkki, P. Koskinen, H. Näveri, H. Leinonen, M. Härkönen, M. Kupari: Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J 18, 1620-1625 (1997). (Pubitemid 27412418)
83. J. P. Pan, T. Y. Liu, S. C. Chiang, Y. K. Lin, C. Y. Chou, W. L. Chan, S. T. Lai: The value of plasma levels of tumor necrosis factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure. J Chin Med Assoc 67, 222-228 (2004).
84. E. J. Birks, V. J. Owen, P. B. J. Burton, A. E. Bishop, N. R. Banner, A. Khaghani, J. M. Polak, M. H. Yacoub: Tumor Necrosis Factor-alpha Is Expressed in Donor Heart and Predicts Right Ventricular Failure After Human Heart Transplantation. Circulation 102, 326-331 (2000). (Pubitemid 30457584)
85. G. Torre-Amione, S. Kapadia, J. Lee, J. B. Durand, R. D. Bies, J. B. Young, D. L. Mann: Tumor Necrosis Factoralpha and Tumor Necrosis Factor Receptors in the Failing Human Heart. Circulation 93, 704-711 (1996).
86. S. R. Kapadia, H. Oral, J. Lee, M. Nakano, G. E. Taffet, D. L. Mann: Hemodynamic Regulation of Tumor Necrosis Factor-alpha Gene and Protein Expression in Adult Feline Myocardium. Circ Res 81, 187-195 (1997). (Pubitemid 27342485)
87. J. Niebauer, H. D. Volk, M. Kemp, M. Dominguez, R. R. Schumann, M. Rauchhaus, P. A. Poole-Wilson, A. J. S. Coats, S. D. Anker: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353, 1838-1842 (1999). (Pubitemid 29251016)
88. D. Bryant, L. Becker, J. Richardson, J. Shelton, F. Franco, R. Peshock, M. Thompson, B. Giroir: Cardiac Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-alpha. Circulation 97, 1375-1381 (1998). (Pubitemid 28182676)
89. F. Franco, G. D. Thomas, B. Giroir, D. Bryant, M. C. Bullock, M. C. Chwialkowski, R.G. Victor, R. M. Peshock: Magnetic Resonance Imaging and Invasive Evaluation of Development of Heart Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-alpha. Circulation 99, 448-454 (1999). (Pubitemid 29051273)
90. T. Kadokami, C. Frye, B. Lemster, C. L. Wagner, A. M. Feldman, C. F. McTiernan: Anti-Tumor Necrosis Factor-alpha Antibody Limits Heart Failure in a Transgenic Model. Circulation 104, 1094-1097 (2001). (Pubitemid 32830389)
91. T. Kubota, G. S. Bounoutas, M. Miyagishima, T. Kadokami, V. J. Sanders, C. Bruton, P. D. Robbins, C. F. McTiernan, A. M. Feldman: Soluble Tumor Necrosis Factor Receptor Abrogates Myocardial Inflammation but Not Hypertrophy in Cytokine-Induced Cardiomyopathy. Circulation 101, 2518-2525 (2000). (Pubitemid 30366257)
92. E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, J. T. Willerson: Randomized, Double-Blind, Placebo- Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-alpha, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation 107, 3133-3140 (2003). (Pubitemid 36793081)
93. T. Tsutamoto, T. Hisanaga, A. Wada, K. Maeda, M. Ohnishi, D. Fukai, N. Mabuchi, M. Sawaki, M. Kinoshita: Interleukin-6 spill over in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31, 391-398 (1998). (Pubitemid 28153460)
94. K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, M. Kinoshita: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36, 1587-1593 (2000).
95. K. C. Wollert, H. Drexler: The role of interleukin-6 in the failing heart. Heart Fail Rev 6, 95-103 (2001). (Pubitemid 32328172)
96. J. Orus, E. Roig, F. Perez-Villa, C. Pare, M. Azqueta, X. Filella, M. Heras, G. Sanz: Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 19, 419-425 (2000). (Pubitemid 30249079)
97. H. Tanner, P. Mohacsi, G. A. Fuller-Bicer, R. Rieben, B. Meier, O. Hess, R. Hullin: Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant 26: 622-629 (1997).
98. Y. Maekawa, T. Anzai, T. Yoshikawa, Y. Sugano, K. Mahara, T. Kohno, T. Takahashi, S. Ogawa: Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodelling after acute myocardial infarction. J Am Coll Cardiol 44, 1510-1520 (2004). (Pubitemid 39303957)
99. R. A. Kelly, T. W. Smith: Cytokines and Cardiac Contractile Function. Circulation 95, 778-781 (1997). (Pubitemid 27091510)
100. A. M. Feldman, A. Combes, D. Wagner, T. Kadakomi, T. Kubota, Y. Y. Li, C. McTiernan: The role oftumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35, 537-544 (2000). (Pubitemid 30167009)
101. I. Buschmann, M. Heil, M. Jost, W. Schaper: Influence of inflammatory cytokines on arteriogenesis. Microcirculation 10, 371-379 (2003). (Pubitemid 39004263)
102. M. Nian, P. Lee, N. Khaper, P. Liu: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94, 1543-1553 (2004). (Pubitemid 38856961)
103. P. Roth, E. R. Stanley: The biology of CSF-1 and its receptor. Curr Top Microbiol Immunol 181, 141-167 (1992).
104. S. Minatoguchi, G. Takemura, X. Chen, N. Wang, Y. Uno, M. Koda, M. Arai, Y. Misao, C. Lu, K. Suzuki, K. Goto, A. Komada, T. Takahashi, K. Kosai, T. Fujiwara, H. Fujiwara: Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109, 2572-2580 (2004). (Pubitemid 38720559)
105. L. Postiglione, S. Montagnani, P. Ladogana, C. Castaldo, G. Di Spigna, E. M. Bruno, M. Turano, L. De Santo, G. Cudemo, S. Cocozza, O. de Divitiis, G. Rossi: Granulocyte Macrophage-Colony Stimulating Factor receptor expression on human cardiomyocytes from endstage heart failure patients. Eur J Heart Fail 8, 564-570 (2006). (Pubitemid 44572962)
106. J. T. Parissis, S. Adamopoulos, K. F. Venetsanou, D. G. Mentzikof, S. M. Karas, D. Kremastinos: Clinical and neurohormonal correlates of circulating granulocytemacrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 86, 707-710 (2000).
107. H. Oren, A. R. Erbay, M. Balci, S. Cehreli: Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction: do they affect the outcome of patients? Angiology 58, 45-54 (2007).
108. A. J. Wieczorek, L. A. Marquez, J. M. Nabholtz: Growth factors and cytokines upregulate galatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Hematopoiesis 93, 3379- 3390 (1999). (Pubitemid 29220905)
109. T. Yano, T. Miura, P. Whittaker, T. Miki, J. Sakamoto, Y. Nakamura, Y. Ichikawa, Y. Ikeda, H. Kobayashi, K. Ohori, K. Shimamoto: Macrophage Colony- Stimulating Factor Treatment After Myocardial Infarction Attenuates Left Ventricular Dysfunction by Accelerating Infarct Repair. J Am Coll Cardiol 47, 626-634 (2006). (Pubitemid 43170856)
110. M. Ohtuka, H. Takano, Y. Zou: Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 18, 851-853 (2004).
111. Y. Sugano, T. Anzai, T. Yoshikawa: Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 65, 446-456 (2005). (Pubitemid 40082487)
112. D. Orlic, J. Kajstura, S. Chimenti: Bone marrow cells regenerate infarcted myocardium. Nature 410, 701-705 (2001). (Pubitemid 32290358)